Preservation and Transfer of Hepatitis B Virus Immunity After Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease Patients (Protect Study)

Sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will probably preserve their immune response to vaccinations administered prior to the transplantation and will therefore not need to be revaccinated. Furthermore, SCD patients after haploidentical HSCT might benefit from adoptive transfer of immunity from their donors.
To test the first hypothesis, patients undergoing alemtuzumab/TBI HSCT will be vaccinated with a hepatitis B virus (HBV) vaccine before the transplant. To test the second hypothesis, haploidentical and matched related donors will be vaccinated prior to stem cell donation against HBV. Neither the patient nor the donor may previously have been immunized against HBV in all cohorts. Post-transplantation, the investigators will be able to evaluate whether SCD patients preserve their pre-transplant immune response in the post-transplantation period. Furthermore, the investigators will determine whether donors transfer their immunity to HSCT recipients with SCD disease.

Start Date08 Jun 2021

Sponsor / Collaborator

Academic Medical Center University of Amsterdam

NCT04326803

/ Unknown statusPhase 4IIT

Hepatitis B Virus (HBV) Infection in Haitian Immigrants in Chile: Determination of HBV Genotypes, Viral Escape Mutants and Host Factors Influencing Response to Vaccination

International migration to Chile has sharply increased since 2010. Particularly, Haitian migration now totals approximately 200.000 people. Preliminary results show a high prevalence of hepatitis B infection in this population. Approximately 35% of adult Haitian migrants in Chile have been exposed to hepatitis B infection. In this study the investigators aim to study the clinical and molecular characteristics of this infection and also to assess the serological response to an accelerated schedule of hepatitis B vaccination (0, 1 and 2 months).

Start Date01 Jun 2020

Sponsor / Collaborator

Pontificia Universidad Católica de Chile

NCT04398706

/ CompletedPhase 2

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Primary objectives:
* To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (Groups 5-8)
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in infants (Groups 5-8)
Secondary objectives:
* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in a subset of infants (Groups 5-8)
* To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in a subset of infants (Groups 5-8)
* In toddlers: to describe the Ab responses against Pentacel antigens before and 1 month following injection of Pentacel
* In infants: to describe the Ab responses against antigens of the routine pediatric vaccines (Pentacel, RotaTeq, ENGERIX-B, M-M-RII, and VARIVAX) when administered concomitantly with either SP0202 or Prevnar 13 (at pre-Dose 1 (as applicable) for RotaTeq, Diphteria, Tetanus and Pertussis antigens; at PD3 for ENGERIX-B, RotaTeq, and Pentacel; at PD4 for M-M-RII and VARIVAX])

Start Date22 May 2020

Sponsor / Collaborator

Sanofi Pasteur SA

100 Clinical Results associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

100 Translational Medicine associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

100 Patents (Medical) associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

1,403

Literatures (Medical) associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

01 Oct 2026·HEPATOLOGY RESEARCH

Hepatitis B Virus Infection Status in Japanese Children Prior to Universal Vaccination: Sustained Effectiveness of Mother‐to‐Child Transmission Prevention and Residual Infection Burden

Article

Author: Shimizu, Yosuke ; Kosugiyama, Kiyotaka ; Sakai, Aiko ; Morioka, Ichiro ; Moriuchi, Hiroyuki ; Tajiri, Hitoshi ; Nakashima, Yumiko ; Katsuta, Tomohiro ; Tagawa, Manabu ; Uemura, Yukari ; Sugiyama, Masaya ; Ishida, Akihito ; Sawada, Kota ; Takano, Tomoko ; Imamura, Atsushi ; Mizokami, Masashi ; Sumazaki, Ryo ; Uetake, Kimiaki ; Tanaka, Yasuhito ; Iwane, Shinji ; Ushijima, Kosuke ; Yotsuyanagi, Hiroshi

ABSTRACT:

Aim:

To evaluate the effectiveness of prevention of mother‐to‐child transmission (PMTCT) over 25 years, we conducted a nationwide epidemiological survey through a comprehensive assessment of hepatitis B virus (HBV) markers.

Methods:

Two cohorts were recruited before universal vaccination: children aged 9–10 years undergoing school health checkups (Group 1) and hospital patients 0–15 years of age from 11 hospitals across Japan to assess age and regional differences (Group 2). Hepatitis B surface antigen (HBsAg) and core antibody (anti‐HBc) were measured in both cohorts. HBV‐DNA was tested to evaluate occult HBV infection and viral genotypes in Group 2. Anti‐HBs antibody was measured to estimate HBV vaccine coverage.

Results:

In Group 1 and Group 2, 8125 and 8453 samples were collected, respectively. HBsAg prevalence was 0% in Group 1 and 0.047% in Group 2 using a conventional assay (Lumipulse II HBsAg). Most HBsAg‐positive samples were from children < 4 years. HBsAg‐negative and anti‐HBc‐positive samples were detected in 0.42% of Group 1 and 0.95% of Group 2. Among these samples in Group 2, 10.3% were HBV‐DNA‐positive, indicating occult HBV infection. Genotype C predominated; however, four genotype D cases were identified in Hokkaido. Anti‐HBs positivity among HBV‐uninfected samples at ages 1, 2, 5, 10, and 15 years was 53.4%, 27.5%, 7.5%, 5.6%, and 1.9%, respectively.

Conclusions:

Following the implementation of PMTCT measures in Japan, the prevalence of HBsAg‐positive children was extremely low. However, the prevalence of occult infection and anti‐HBc positivity indicated that some children remained exposed to HBV. To further eradicate HBV infection, universal vaccination was introduced nationwide in 2016.

01 Oct 2026·JAMA Internal Medicine

Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations

Article

Author: Roldan, Giovanni A. ; Davie, Timothy ; Lake, John R. ; Udompap, Prowpanga ; Fletcher, Jesse ; Leventhal, Thomas M.

Importance:

Serologic immunity to hepatitis A virus (HAV) and hepatitis B virus (HBV) protects against acute infection and severe outcomes among high-risk groups; however, contemporary data on population-level immunity remain limited, especially in high-risk populations.

Objective:

To estimate the prevalence and factors associated with serologic immunity in the overall population and across high-risk subgroups, including those with chronic liver disease (CLD), chronic kidney disease, diabetes, and immunosuppression and pregnant people.

Design, Setting, and Participants:

This cross-sectional study used data from the National Health and Nutrition Examination Survey from January 2017 to August 2023 and included adults aged 20 years or older with available HAV and HBV serologic test results. Data were analyzed from January 3 to May 10, 2026.

Main Outcomes and Measures:

The primary outcomes were the prevalence of serologic immunity to HAV, defined by hepatitis A antibody positivity, and HBV, defined by hepatitis B surface antibody positivity, with vaccine-derived immunity specifically identified by surface antibody positivity in the absence of hepatitis B core antibodies. Data were weighted to generate nationally representative estimates of the US adult population. Multivariable survey-weighted logistic regression models were used to identify independent factors associated with viral hepatitis immunity.

Results:

Among 13 514 individuals, representing an estimated 226.1 million US adults (mean [SE] age, 48.65 [0.40] years; 51.76% female), 39.5% (95% CI, 37.7%-41.3%) demonstrated serologic immunity to hepatitis A, corresponding to approximately 89.4 million individuals. For HBV, 27.1% (95% CI, 25.8%-28.4%) demonstrated serologic immunity, corresponding to approximately 61.3 million individuals, while vaccine-derived immunity was present in 25.2% (95% CI, 23.9%-26.5%). In adjusted models, HAV immunity was associated with younger age (eg, 20-29 vs ≥65 years: adjusted odds ratio [AOR], 0.51; 95% CI, 0.44-0.60); lower educational attainment (eg, &lt;grade 9 vs college graduate or above: AOR, 0.32; 95% CI, 0.24-0.42); non-Hispanic Black (AOR, 1.67; 95% CI, 1.34-2.09), Mexican American (AOR, 4.22; 95% CI, 3.42-5.21), other Hispanic (AOR, 2.01; 95% CI, 1.60-2.54), non-Hispanic Asian (AOR, 3.03; 95% CI, 2.45-3.76), and multiracial or other (AOR, 1.36; 95% CI, 1.04-1.79) race and ethnicity; being born outside the US (AOR, 4.54; 95% CI, 3.74-5.52); and liver disease awareness (OR, 1.65; 95% CI, 1.29-2.09). Obesity was associated with lower odds of HAV immunity (AOR, 0.83; 95% CI, 0.72-0.96). Vaccine-derived HBV immunity was associated with younger age (eg, 20-29 vs ≥65 years: AOR, 0.18; 95% CI, 0.15-0.23), female sex (AOR, 1.36; 95% CI, 1.18-1.56), non-Hispanic Asian (AOR, 1.47; 95% CI, 1.17-1.86) and non-Hispanic Black (AOR, 1.15; 95% CI, 1.00-1.32) race and ethnicity, and higher educational attainment (eg, &lt;grade 9 vs college graduate or above: AOR, 3.29; 95% CI, 2.35-4.61). In high-risk subgroups, HAV immunity ranged from 26.7% (95% CI, 18.9%-34.4%) for metabolic dysfunction–associated alcohol-related liver disease to 63.7% (95% CI, 50.0%-77.4%) for chronic HBV infection, while HBV vaccine-derived immunity ranged from 14.0% (95% CI, 11.3%-16.6%) for chronic kidney disease to 38.6% (95% CI, 28.0%-49.1%) for pregnancy.

Conclusions and Relevance:

This cross-sectional study found that population-level serologic immunity to HAV and HBV was suboptimal and substantial susceptibility persisted across high-risk clinical subgroups. These findings highlight persistent gaps in viral hepatitis protection and support targeted, systematic vaccination strategies for HAV and HBV, especially among high-risk populations.

01 Sep 2026·International Health

Coverage and determinants of hepatitis B virus vaccine uptake among children aged 12–36 months in Ethiopia: an analysis of the 2016 Ethiopian Demographic and Health Survey

Article

Author: Lim, Aaron G ; Alamneh, Tesfa Sewunet ; Walker, Josephine G ; White, Kathleen Kenyatta

Abstract:

Background:

In Ethiopia, chronic hepatitis B virus (HBV) prevalence is high (∼6%) and infant vaccination targets are unmet. We assessed HBV vaccination uptake and associations with parental sociodemographic and obstetric factors among children (aged 12–36 months) in Ethiopia.

Methods:

We utilised the 2016 Ethiopian Demographic and Health Survey. We included a weighted sample of 3,855 children (aged 12–36 month) to assess HBV vaccination coverage level (none, incomplete, and complete) and its spatial distribution. Additionally, we identified associated factors of HBV vaccination coverage level using ordinal logistic regression.

Results:

Overall, 51.2% of children received complete HBV vaccination, with wide regional variation. Older maternal age (adjusted odds ratio (AOR)=1.05, 95% confidence interval (CI): 1.02–1.07), better maternal education level (mean AOR=1.66–2.08), higher household wealth quantile (mean AOR=1.51–2.32), distance to a healthcare facility not a big problem (AOR=1.54, 95% CI: 1.25–1.89), and complete maternal continuum care utilisation (AOR=2.59, 95% CI: 1.25–5.30) were positively associated with HBV vaccination coverage, while higher number of children in the household (AOR=0.86, 95% CI: 0.79–0.92) was negatively associated.

Conclusions:

HBV vaccination coverage falls below World Health Organization (WHO) targets in Ethiopia and has substantial regional variation. Targeted vaccination campaigns for mothers in lower socioeconomic groups and larger families may improve vaccination coverage.

News (Medical) associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

27 Mar 2026

·www.fiercepharma.com

Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo

Takeda's $1.3 billion restructuring plan, semaglutide generic launches in India and Gilead's $2.2 billion Ouro acquisition made our news this week. Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's semaglutide reached India in chaotic fashion. Gilead Sciences is paying up to $2.2 billion to purchase a Chinese "NewCo." And more.1. Takeda targets $1.3B in cost savings in further restructuringTakeda is launching another round of restructuring, aiming to achieve 200 billion Japanese yen ($1.26 billion) in annual gross savings by its 2028 fiscal year. Resources will be reallocated to support upcoming launches, late-stage programs and strategic technology investments. To achieve increased efficiency, the company expects to incur 150 billion yen in restructuring expenses in fiscal 2026. 2. With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper genericsGenerics to Novo Nordisk’s semaglutide have launched in India. More than 10 brands have launched online, and shortages have already happened despite inventory build-ups by companies, according to a March 26 note by Jefferies. For injectable versions, the monthly prices range between 1,290 rupees ($13.7) to 4,500 rupees ($47.8). “Companies are testing the waters with demand and supply, and they expect the market to settle down in the next few months,” Jefferies’ analysts said.3. Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for GalapagosGilead Sciences is paying $1.675 billion upfront for Ouro Medicines, a “NewCo” built on ex-China rights to a BCMAxCD3 T-cell engager from China’s Keymed Biosciences and funding from GSK and Monograph Capital. Known as gamgertamig, or OM336, the drug is being studied for autoimmune disorders. Gilead is planning for its partner Galapagos to essentially absorb Ouro.4. Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&DNovartis said it will invest 1.5 billion yuan ($220 million) to upgrade its manufacturing facility in Beijing and will spend another 1.8 billion yuan to initiate a second phase of its Shanghai R&D campus. “China is crucial to Novartis’ long-term development and innovation,” CEO Vas Narasimhan said at the 2026 China Development Forum.5. Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's RybrevantA global phase 3 trial of Dizal’s Zegfrovy has met its primary endpoint of progression-free survival in first-line EGFR exon 20-mutated non-small cell lung cancer, the Chinese biotech announced. The oral drug—as a monotherapy—beat chemo where Johnson & Johnson’s injectable Rybrevant achieved in combination with chemo. 6. Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in ChinaThe United Laboratories, licensor of Novo Nordisk’s GLP-1/GIP/glucagon triple agonist, reported a Chinese midphase win against semaglutide in Type 2 diabetes. After 24 weeks of once-weekly injections, levels of HbA1c fell up to 2.16% in the UBT251 cohorts, compared to declines of 1.77% for semaglutide. Novo plans to start a global phase 2 trial in diabetes this year.Other News of Note: 7. Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech8. Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order9. Innovent delivers first year of net profit amid growing sales, global partnerships (release)10. InnoCare achieves profitability for the first time thanks to 2 BD deals (release)11. Hengrui posts 13% annual revenue growth, but quarterly profit misses forecasts (Reuters)12. Sino Biopharm touts 26% sales growth from innovative drugs (release)13. Innovent sees path to China approval after eye disease drug matches Eylea in phase 314. WuXi Bio's record number of new projects in 2025 leaned heavily on US clients15. Akeso advances oncology strategy as revenue jumps 44% (release, PDF)16. Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream17. BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data18. GSK partners with Shanghai Pharma to bring hepatitis B vaccine back to China (Yicai)

Phase 3AcquisitionClinical ResultVaccinePhase 2

14 Jan 2026

·www.biospace.com

JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales

iStock, nito100 Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration. “It’s a good time to do vaccine BD and M&A,” according to Sanofi CEO Paul Hudson. While vaccine sentiment is suffering amid the Trump administration’s rhetoric, Hudson says he’s playing the long game with Sanofi’s acquisition of Dynavax . “With the uncertainty, if you’re a short-term thinker, you don’t move. If you’re a long-term thinker—which is what we have to be—then there are less people to compete against to make acquisitions,” Hudson told reporters at a media breakfast in San Francisco on day three of the J.P. Morgan Healthcare Conference. To end 2025, Sanofi offered $2.2 billion to buy Dynavax. The center of that deal is the hepatitis B vaccine Heplisav-B. That the vaccine is for adults could help Sanofi overcome some of the vaccine hesitancy that is rising, particularly in America, Hudson said. “We know that the sensitivities are less in the adult context.” And it was those sensitivities that set the stage for the French drugmaker to pay what Hudson called an “appropriate price” for Dynavax. Elsewhere on the company’s business development (BD) bingo card, he also pointed to Sanofi’s July 2025 acquisition of Vicebio for $1.6 billion, scooping up a combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). “Those things will launch 5, 6, 7, 8 years from now. And so we have to assume that there’ll be a new administration or two between now and then,” Hudson said. “We don’t know what their sensitivities will be, but it’s okay, as long as there’s some objectivity in the regulator.” Hudson hinted that there could be more deals to come in the vaccine space. Sanofi’s legacy vaccine sales fell 8% in the third quarter and Hudson is predicting similar “softness” in the quarters to come. Hudson reiterated that the sales decline can be pinned on the “misinformation that is going around.” He noted the rise in measles cases as people opt out of vaccines. “We think it will settle down and we’ll move through it,” Hudson said. Sanofi has not provided guidance for 2026 yet. Hudson also spoke to recent vaccine schedule updates and other antivaccine actions at the Department of Health and Human Services (HHS). The CEO suggested that people are capable of educating themselves when it comes to vaccines in partnership with their care providers. “The vast majority of people understand the benefit of vaccines and their lives and generations of their family have been protected that way,” Hudson said. “Not everybody looks to the top of the HHS to get people with their guidance on how to live their lives.” He continued: “So I think people should be respectful of all guidance given, but I think talking to their own healthcare professional is still probably the best thing to do.” Vaccines Pesky ‘Macro Factors’—aka RFK Jr.—Come for Vaccine Pharmas’ Wallets Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs. November 7, 2025 · 4 min read · Annalee Armstrong Read more The Next Moment Vicebio and Dynavax’s programs may be years out from FDA review, but Sanofi’s flu-COVID combo, licensed from Novavax, is not. Hudson expects regulatory review to happen in 2027 or 2028. That shot is “going to be the next moment, I think, for an acceleration on vaccine utilization,” Hudson said. The product will offer convenience with a one-and-done approach for both infectious diseases. And it will be the only non-mRNA COVID shot available in the U.S. for those who do not want to receive a shot featuring that technology. “We think people are still very vaccine literate. We think they understand the reactogenicity or the tolerability challenges of mRNA,” Hudson said. Those post-vaccine reactions may have been tolerated during the global pandemic, but that’s not the case anymore, the CEO explained. He expects Sanofi will garner the over-55 and over-65 markets, particularly as the combo can offer a high dose needed for older people, who are at higher risk of death from the flu. “While there may be debates on Facebook and other places, the over-65s, I think, are highly motivated to get protected,” Hudson said, “because they know they are the ones that are most vulnerable.”

VaccineAcquisitionmRNA

29 Dec 2025

·www.pharmaceutical-technology.com

Sanofi buys hep B vaccine maker for $2.2bn

Sanofi’s executive vice president of vaccines Thomas Triomphe said the deal “brings new option to our portfolio”. Image credit: Below the Sky via Shutterstock.com. Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former’s pipeline amid significant vaccine policy changes in the US. The transaction, for a price of $15.50 per share in cash, is expected to close in the first quarter of 2026. Through the deal, Sanofi will acquire Dynavax’s hepatitis B vaccine HEPLISAV-B. The product won approval in the US and Europe in 2017 and 2021, respectively. Sanofi does not currently have a hepatitis B vaccine in its portfolio. The French drugmaker previously won approval for a hepatitis B vaccine in a joint venture with MSD, though the latter company now commercialises the jab, which is known under the HBVaxPro and Recombivax HB brand names in Europe and the US, respectively. Heplisav-B is administered via a two-dose regimen delivered within one month, unlike GSK’s Engerix-B and MSD’s Recombivax HB. These rival products are given in three doses over six months. With the Dynavax acquisition, Sanofi is adding a strong revenue avenue for the virus that causes serious liver infection. HEPLISAV-B generated sales of $268.4m in 2024, with Dynavax forecasting net product revenue of between $305m and $325m for 2025. GlobalData forecasts HEPLISAV-B will reach $677m in annual sales in 2031. GlobalData is the parent company of Pharmaceutical Technology . GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence William Blair analyst Matt Phipps said: “While the deal value does come slightly below our net present value for Heplisav of $2.6bn, we believe the acquisition makes sense given growing regulatory concerns around vaccines and investor questions on management’s strategy for value creation.” Earlier in December, the US Centers for Disease and Prevention (CDC) changed its guidance to no longer recommend that all US newborns receive the hepatitis B vaccine. The significant policy changes have created volatility in the infectious disease vaccine sector, along with catalysing backlash from several medical bodies . The jewel in Dynavax’s pipeline is its shingles vaccine candidate, currently in a Phase I/II trial. In results announced in August 2025, the jab, dubbed Z-1018, demonstrated comparable efficacy to GSK’s blockbuster Shingrix – a product that dominates the shingles market. However, Z-1018 had fewer local and systemic post-injection reactions, which might give it a market advantage on tolerability. About one in three people in the US develop shingles at least once in their lives, according to the CDC. Shingrix generated £3.4bn globally for GSK in 2024, representing the size of the shingles market. Sanofi’s executive vice president of vaccines Thomas Triomphe said: “Dynavax’s marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan.” Phipps commented that: “Sanofi is a logical acquisition partner for Dynavax given the company has extensive vaccine capabilities but the portfolio does not have an adult hepatitis B or shingles programme.” Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards . A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines. Discover the Impact

VaccineDrug ApprovalAcquisitionClinical Result

100 Deals associated with Hepatitis B vaccine(GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
D04432	-	J07BC01	DBSALT001978

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	United States	GlaxoSmithKline LLC	28 Aug 1989

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01311674 (CTgov)	Phase 3	Hepatitis B	141	hepatitis B vaccine (Schedule 1- Standard Dose Primary Vaccination Series)	crbtlrgpbt(jwxicfzwnw) = ecdvoeeutk zdchvqtllw (hbaefgdczj, 3065.6) View more	-	17 Aug 2021
				hepatitis B vaccine (Schedule 2 - High Dose Primary Vaccination Series)	crbtlrgpbt(jwxicfzwnw) = xigidnmnat zdchvqtllw (hbaefgdczj, 1097.3) View more
NCT02003703 (Pubmed \| JAMA Netw Open)	Phase 3	HIV Infections	107	Hepatitis B Revaccination (High-dose HBV vaccination)	bpxthhlcpw(hjbhjvxdbq) = amglijiunx cagibctbzj (wuacvvamnr ) View more	-	02 Aug 2021
				Hepatitis B Revaccination (Standard-dose HBV vaccination)	bpxthhlcpw(hjbhjvxdbq) = mfjjpnszxe cagibctbzj (wuacvvamnr ) View more
ECCO2021	Not Applicable	Inflammatory Bowel Diseases	104	Intra-dermal hepatitis B vaccination with topical imiquimod	teldslovjz(fhusryhaup) = vvkfmanjjg gawakeyuml (behmbgfgdl ) View more	Positive	02 Jul 2021
				Intra-muscular recombinant hepatitis B vaccine with topical aqueous cream	teldslovjz(fhusryhaup) = rtotwgzzrm gawakeyuml (behmbgfgdl ) View more
NCT03393754 (PROTECT, EASL2020)	Phase 3	Hepatitis B	1,607	Engerix-B (Sci-B-Vac 10 Î¼g)	lwdplclfil(fetjrnzpfx) = zeszkbkowd uutduryhrk (bexdgfivpx ) View more	Positive	27 Aug 2020
				Engerix B 20 Î¼g	lwdplclfil(fetjrnzpfx) = ntvsyrpklp uutduryhrk (bexdgfivpx ) View more
NCT02169674 (CTgov)	Phase 4	Hepatitis B	359	EngerixB, GlaxoSmithKline Vaccines (10-11 Year-olds)	qcwsolphos = sjyopomylt liuiyghyma (msspicuxdp, wiclhkfsov - alfacityvg) View more	-	21 Mar 2019
				EngerixB, GlaxoSmithKline Vaccines (15-16 Year-olds)	qcwsolphos = znxvwmcvkw liuiyghyma (msspicuxdp, tlygbnptkr - wzdtgqzktx) View more
NCT02798952 (CTgov)	Phase 4	Hepatitis B	302	Engerix-B Kinder+Infanrix hexa	bhvlqkxihd(uobabihxvw) = aguyrgvqsx wuvzmaavtq (undigjpspq, gduznbkadx - jerbzdavkl) View more	-	01 Feb 2019
ASN2018	Not Applicable	anti-HBsAg titer	28	Standard Double-Dose Intramuscular Vaccine	qoglaulhhh(unhsbbkxdq) = There were no reports of adverse events associated with intradermal dosing xcbinsgvml (cwnezznghi )	Positive	23 Oct 2018
NCT02901951 (CTgov)	Phase 4	Hepatitis B	106	Engerix-B	wsrchcoiur = hpdqcchdmi drhvvikuud (rhfihhzskm, bxrlycvpuq - jmxoklzrcw) View more	-	03 Aug 2018
NCT01817725 (CTgov)	Phase 1	Hepatitis B, Chronic	20	HBV vaccine	itdshfegah(lutmkfprpr) = odvigfgkck likqyidlvn (jmubzivekc, 0.48) View more	-	02 May 2017
NCT01847430 (Pubmed \| Vaccine)	Phase 4	Hepatitis B	303	Hepatitis B vaccine challenge dose	qrkgciemxe(xwyeptcrgx) = ialcspynig jcfaajhljv (jxzfmrbyxe, 94.2 - 98.6) View more	-	23 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis